USPTO Examiner GREENE IVAN A - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18766716METHOD FOR TREATING CANCER CELLS WITH A CU/AG PARTICLE COMPOSITIONJuly 2024September 2024Allow200YesNo
18602710MULTISTAGE CALCINATION METHOD FOR MAKING HOLLOW SILICA SPHERESMarch 2024August 2024Allow510YesNo
18599582METHOD FOR DECREASING COLORECTAL CANCER CELLSMarch 2024June 2024Allow300YesNo
18545415SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NEUROTROPHIC AND NEUROPROTECTIVE COMPOSITIONSDecember 2023April 2025Abandon1610NoNo
18541054PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFDecember 2023February 2025Abandon1410NoNo
18374334HOLLOW SILICA SPHERES WITH NESTED IRON OXIDE PARTICLESSeptember 2023February 2024Allow410YesNo
18231862NANOCOMPOSITE COMPOSITIONS COMPRISING MULTI-VALENT METAL MATERIAL AND IMMOBILIZED QUAT MATERIAL, METHODS OF MAKING THE COMPOSITIONS AND METHODS OF USING THE COMPOSITIONSAugust 2023February 2025Abandon1810NoNo
18366927SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR PHARMACEUTICAL COMPOSITIONSAugust 2023January 2025Abandon1810NoNo
18366945SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONSAugust 2023January 2025Abandon1810NoNo
18220599COMPOSITION FOR TREATING BONE LOSSJuly 2023January 2025Abandon1830NoNo
18220560COMPOSITION FOR TREATING BONE LOSSJuly 2023May 2025Abandon2340NoNo
18349753BIOLOGICALLY ACTIVE SUBSTANCE UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAMEJuly 2023February 2025Abandon2011NoNo
18343812CANCER TREATING COMPOSITION CONTAINING COPPER-SILVER-PHOSPHATE NANOPARTICLESJune 2023May 2025Allow2331YesNo
18343803COPPER-SILVER-PHOSPHATE NANOPARTICLE MANUFACTURING METHODJune 2023January 2025Allow1911NoNo
18200055HOLLOW SILICA SPHERES WITH NESTED IRON OXIDE PARTICLESMay 2023August 2024Allow1410YesNo
18301505METHOD FOR KILLING COLORECTAL CANCER CELLSApril 2023November 2024Allow1920YesNo
18116820COMPOSITION FOR TREATING BONE LOSSMarch 2023February 2025Abandon2441NoNo
18169051CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAMEFebruary 2023October 2024Allow2010NoNo
18087137COMPOSITE IMPLANTSDecember 2022January 2024Abandon1311NoNo
17956875TREATMENT METHOD FOR COLON CANCERSeptember 2022January 2023Allow300YesNo
17956887TREATMENT METHOD FOR COLON CANCERSeptember 2022April 2023Allow610NoNo
17823750METHOD FOR MAKING SOLID SILICA SPHERESAugust 2022August 2024Allow2320YesNo
17893633HYBRID FRAGRANCE ENCAPSULATE FORMULATION AND METHOD FOR USING THE SAMEAugust 2022June 2025Allow3410NoNo
17886329BIOMARKERS FOR NANOPARTICLE COMPOSITIONSAugust 2022February 2025Abandon3111NoNo
17806839PEDIATRIC FORMULATIONJune 2022March 2024Abandon2111NoNo
17737561NICOTINAMIDE ADENINE DINUCLEOTIDE ACTIVATOR AND USE THEREOFMay 2022October 2024Abandon3021NoNo
17661172CANNABINOID COMPOSITIONS AND PROCESSES FOR MAKING SAMEApril 2022December 2023Abandon2001NoNo
17730820COMPOSITION, PARTICULATE MATERIALS AND METHODS FOR MAKING PARTICULATE MATERIALSApril 2022June 2023Allow1400YesNo
17768132SUPERFINE COMPOUNDS AND PRODUCTION THEREOFApril 2022May 2025Abandon3741YesNo
17715970STARCH-BASED DOUBLE-LOADED FUNCTIONAL NANO PARTICLE AS WELL AS PREPARATION METHOD AND APPLICATIONApril 2022July 2024Allow2711NoNo
17711863COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERSApril 2022February 2024Allow2210NoNo
17579087METHOD OF PREPARING NANOPARTICLES FOR CANCER TREATMENTSJanuary 2022January 2024Allow2411YesNo
17561540METHODS FOR TREATMENT OF BLADDER CANCER WITH GEMCITABINEDecember 2021February 2025Abandon3820YesYes
17552412PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFDecember 2021January 2024Abandon2510NoNo
17519900Esteramine CompositionsNovember 2021March 2025Abandon4101NoNo
17604138METHOD FOR REMOVING BIOFILMOctober 2021May 2025Abandon4311NoNo
17389680OPHTHALMIC COMPOSITIONS FOR REMOVING MEIBUM OR INHIBITING MEIBUM BUILDUPJuly 2021March 2025Abandon4431NoNo
17384126LASER ENHANCER COMPOSITION FOR IMPROVING MELASMA, WRINKLES, SKIN TIGHTENING, PORES, AND ACNEJuly 2021February 2024Abandon3111NoNo
17351337NANOPARTICLE-ENCAPSULATED CANNABINOIDS AND METHODS FOR MAKING AND USING SAMEJune 2021November 2024Abandon4131NoNo
17352245PREPARATION OF NANOPARTICLES USING MODIFIED ICE-TEMPLATEJune 2021February 2024Abandon3221NoNo
17318339MULTI-COATED NANOPARTICLES COMPRISING MULTIPLE COATING LAYERS OF CHITOSAN AND POLYGLUTAMIC ACID, COMPOSITION FOR SKIN CARE COMPRISING THE SAME AND METHOD FOR MANUFACTURING THE SAMEMay 2021April 2025Allow4741YesNo
17306403DISSOLVING FILM FOR DELIVERY OF AN ACTIVE AGENTMay 2021October 2023Abandon3011NoNo
17240405Nanoparticle Depot For Controlled And Sustained Gene DeliveryApril 2021January 2025Abandon4540YesNo
17239262NANOEMULSION HYDROPHOBIC SUBSTANCESApril 2021February 2023Abandon2231YesNo
17231231METHODS OF TREATMENT USING TITANIUM AND SILVER NANOPARTICLES MADE WITH AN INTRACELLULAR EXTRACT OF FOMES FOMENTARIOUSApril 2021September 2023Abandon2921YesNo
17228224DUAL-TARGETING LIPID-POLYMER HYBRID NANOPARTICLESApril 2021November 2024Abandon4341NoNo
17205521METHOD FOR TREATMENT OF CORONAVIRUS INFECTIONMarch 2021April 2025Abandon4931NoYes
17188401PHARMACEUTICAL COMPOSITIONS OF RIVAROXABANMarch 2021September 2024Abandon4331NoNo
17178808POLYMER-CYCLIC MOLECULE STRUCTURE AND METHOD FOR PRODUCING THE SAMEFebruary 2021September 2024Abandon4331YesNo
17267187INJECTABLE PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFORFebruary 2021December 2023Abandon3401NoNo
17259371A BIOLOGICALLY ACTIVE SUBSTANCE UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAMEJanuary 2021November 2023Abandon3440YesNo
17136251METAL EXTRACTION SHEET, MASK PACK INCLUDING SAME AND METHOD FOR MANUFACTURING THE METAL EXTRACTION SHEETDecember 2020August 2024Abandon4331YesNo
16973721USE OF PHOSPHORUS-BASED MATERIAL IN PREPARATION OF MEDICAMENT FOR TREATING TUMORSDecember 2020December 2024Abandon4821YesNo
17106625PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOFNovember 2020April 2022Abandon1711NoNo
17079214CANNABINOID-CONTAINING ORAL THIN FILM FORMULATIONSOctober 2020May 2022Abandon1920YesNo
17067297CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAMEOctober 2020April 2023Allow3011YesNo
16990634CORE-SHELL STRUCTURE, PREPARATION, MEDICINE FOR EXTERNAL APPLICATION, TAPE AGENT AND COSMETIC PRODUCTAugust 2020September 2024Allow4920YesYes
16931939PRODUCTION OF NANOPARTICLESJuly 2020May 2023Abandon3421NoNo
16932699CANNABINOID COMPOSITIONS AND PROCESSES FOR MAKING SAMEJuly 2020May 2022Abandon2231YesNo
16925478DISPERSIBLE POWDER AND COSMETICJuly 2020March 2024Abandon4430NoNo
16906028HYDROGEL INCLUSION COMPLEX INCLUDING PHYSIOLOGICALLY ACTIVE MATERIAL BOUND TO THERMOSENSITIVE POLY(PHOSPHAZENE) BY HOST-GUEST INTERACTION USING BETA-CYCLODEXTRIN AND USE THEREOFJune 2020May 2025Abandon5841NoNo
16890172FUNCTIONAL MEMBER AND METHOD OF FABRICATING THE SAMEJune 2020February 2023Abandon3301NoNo
16884161HIGH ABSORPTION MINERALSMay 2020February 2025Abandon5741YesNo
16880309COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTSMay 2020July 2024Abandon5040NoNo
16764551METAL-NUCLEIC ACID NANOPARTICLE, PREPARATION METHOD THEREFOR AND USE THEREOFMay 2020July 2022Allow2611YesNo
16760183RADIATION STERILIZED HYDROGELS, MEDICAL DEVICES INCLUDING RADIATION STERILIZED HYDROGELS AND METHODS OF MAKING THE SAMEApril 2020January 2025Abandon5631NoYes
16850468MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIAApril 2020March 2022Allow2310NoNo
16652486COMPOSITIONS AND METHODS FOR TREATING PSEUDOANEURYSMMarch 2020July 2023Abandon4021NoNo
16783548UPCONVERSION NANOPARTICLE, HYALURONIC ACID-UPCONVERSION NANOPARTICLE CONJUGATE, AND A PRODUCTION METHOD THEREOF USING A CALCULATION FROM FIRST PRINCIPLESFebruary 2020January 2023Abandon3621NoNo
16773723COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERSJanuary 2020December 2021Allow2320NoNo
16618219METHOD OF PREPARING SUSTAINED-RELEASE DRUG MICROPARTICLES WITH EASY RELEASE CONTROLNovember 2019November 2024Abandon6051NoNo
16678671MULTIFUNCTIONAL COATED POWDERS AND HIGH SOLIDS DISPERSIONSNovember 2019February 2024Abandon5231YesNo
16676195MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGESNovember 2019July 2020Allow810YesNo
16673083SACCHARIDE-BASED, ORAL MUCOADHESIVE DELIVERY SYSTEM FOR PHARMACEUTICAL COMPOSITIONSNovember 2019September 2023Abandon4721NoNo
16673038SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONSNovember 2019September 2023Abandon4721NoNo
16596304Deterring Abuse of Pharmaceutical Products and AlcoholOctober 2019April 2022Abandon3010NoNo
16493937USE OF TALC FOR PEARLESCENCE IN LIQUID COMPOSITIONSSeptember 2019July 2023Abandon4621NoNo
16565410Microorganism-Resistant Materials and Associated Devices, Systems, and MethodsSeptember 2019August 2024Abandon5941NoNo
16557068MANUFACTURING METHOD FOR SOFTGEL CAPSULE CONTAINING SOLID AND LIQUID FORMULATIONS AS CORE INGREDIENTAugust 2019January 2022Abandon2810YesNo
16544151Thin Aluminum Pigments Having A Narrow Thickness Distribution, Method For Producing Same, And Use Of Aluminum PigmentsAugust 2019July 2022Allow3521YesYes
16537191DRUG SUSTAINED-RELEASE CARRIER AND METHOD FOR PRODUCING SAMEAugust 2019March 2024Abandon5541NoNo
16534728METHODS OF TREATING HYPERPIGMENTATION DISORDERSAugust 2019September 2024Abandon6061YesNo
16475959BIOCOMPATIBLE PHOTOTHERMAL COMPOSITION FOR TREATMENT OF CANCER AND SKIN DISEASESAugust 2019December 2022Abandon4141NoNo
16506850IMPLANTABLE SOLID DOSAGE FORMJuly 2019August 2021Allow2511YesNo
16476838COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERSJuly 2019June 2021Abandon2310NoNo
16455438MULTIFUNCTIONAL BIODEGRADABLE CARRIERS FOR DRUG DELIVERYJune 2019November 2023Abandon5241YesNo
16447382Oil-In-Water Type Emulsion Cosmetic CompositionJune 2019February 2021Abandon2010NoNo
16415550EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOFMay 2019June 2023Allow4921YesYes
16403049METHOD FOR TREATING NEOPLASMS USING HOLLOW SILICA SPHERESMay 2019August 2022Allow4031YesYes
16340459PARTICLES WITH VARIABLE REFRACTIVE INDEXApril 2019January 2023Abandon4501NoNo
16339404SPHERICAL MICROPARTICLES WITH POLYESTER WALLSApril 2019June 2022Allow3921YesNo
16332199IMPLANTABLE MEDICAL DEVICES HAVING COATING LAYERS WITH ANTIMICROBIAL PROPERTIES BASED ON NANOSTRUCTURED HYDROXYAPATITESMarch 2019March 2022Abandon3621NoNo
16331269OXYBUTYNIN-CONTAINING TRANSDERMAL ABSORPTION PREPARATIONMarch 2019August 2022Abandon4140YesNo
16279794PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND USE OF SAMEFebruary 2019November 2020Abandon2130NoNo
16260159Methods To Prepare Haloamines Using At Least One Solid Reactant And Products Made TherefromJanuary 2019October 2024Abandon6031NoYes
16314219EXCIPIENT AND TABLETDecember 2018July 2022Abandon4240YesNo
16310289USE OF CERTAIN COMPOUNDS TO MODIFY, REDUCE, OR ELIMINATE OFF-NOTESDecember 2018October 2020Abandon2201NoNo
16216439GAS DISPERSION MANUFACTURE OF NANOPARTICULATES, AND NANOPARTICULATE-CONTAINING PRODUCTS AND PROCESSING THEREOFDecember 2018December 2022Abandon4841NoNo
16206869NANOEMULSION HYDROPHOBIC SUBSTANCESNovember 2018March 2021Allow2731YesYes
16306339ANTIMICROBIAL AGENT COMPRISING CARBON-GROUP NON-OXIDE NANOPARTICLES, AND PRODUCTION METHOD THEREFORNovember 2018December 2021Abandon3621NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GREENE, IVAN A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
45
Examiner Affirmed
33
(73.3%)
Examiner Reversed
12
(26.7%)
Reversal Percentile
41.1%
Lower than average

What This Means

With a 26.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
144
Allowed After Appeal Filing
22
(15.3%)
Not Allowed After Appeal Filing
122
(84.7%)
Filing Benefit Percentile
15.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GREENE, IVAN A - Prosecution Strategy Guide

Executive Summary

Examiner GREENE, IVAN A works in Art Unit 1619 and has examined 569 patent applications in our dataset. With an allowance rate of 18.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.

Allowance Patterns

Examiner GREENE, IVAN A's allowance rate of 18.6% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GREENE, IVAN A receive 3.15 office actions before reaching final disposition. This places the examiner in the 97% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GREENE, IVAN A is 44 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +8.0% benefit to allowance rate for applications examined by GREENE, IVAN A. This interview benefit is in the 40% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 3.6% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 10.0% of cases where such amendments are filed. This entry rate is in the 5% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 37.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 33% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 45.1% of appeals filed. This is in the 8% percentile among all examiners. Of these withdrawals, 21.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.1% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 60% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.